Adoram Therapeutics Secures Pre-Seed Investment to Advance Innovative Cancer Immunotherapy and Inflammation Programs

Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in CHAPTER-1 OLE who had reached week 62 reported improved health-related quality of life Ongoing RAPIDe-2 extension study includes efficacy data from seven upper airway, including laryngeal, attacks; median time

SOTIO Biotech today presented the first preclinical data on SOT109, a novel antibody-drug conjugate (ADC) targeting cadherin-17 (CDH17). The data highlight SOT109's promising activity and tolerability profile across multiple disease models, reinforcing its potential to become a best-in-class therapeutic for the treatment of colorectal cancer and other gastrointestinal (GI) cancers. The findings we

Findings highlight underexplored role of intestinal brush border in protein digestion, and its vulnerability to inflammatory damage in celiac disease Review discusses potential benefits of supplementing brush border exopeptidase activity in celiac disease patients

InVirtuoLabs, a biotech startup founded in Lugano in 2024, has closed its first funding round of €2.85 million, marking a decisive acceleration in pharmaceutical research. Leveraging generative artificial intelligence and advanced molecular simulations, the startup aims to drastically reduce the time and cost of drug development, making treatments more accessible.